Clinical Trial: Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07791836) titled 'Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study' on June 29.

Brief Summary: This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).

Study Start Date: Aug. 23

Study Type: OBSERVATIONAL

Condition: Hemophilia A Hemophilia

Intervention: DRUG: efmoroctocog alfa

This study assesses patients with a history of at least 10 exposure days (EDs) to recombinant factor VIII with Fc fusion (Coageight) within the 12 months prio...